# A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

Study · id `cardio:ct-nct07373613` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07373613](<https://clinicaltrials.gov/study/NCT07373613>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07373613

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT07373613. Randomized; double masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2027-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT07373613, source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)
- Planned start: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT07373613, source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)
- Primary completion: 2027-02-01 (anticipated) (ClinicalTrials.gov record NCT07373613, source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)
- Completion: 2027-02-01 (anticipated) (ClinicalTrials.gov record NCT07373613, source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07373613, source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07373613-2026-01-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): BR1400-1
- Intervention (Drug): BR1400-2
- Intervention (Drug): BR1400-3
- Intervention (Drug): BR1400-4
- Intervention (Drug): BR1400-5
- Intervention (Drug): BR1400-A
- Intervention (Drug): BR1400-B
- Intervention (Drug): BR1400-C
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 32a91c01d9d2f74d7e93516c65ab442c713ce452b89bd5c1a2c903736dd7a342
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
